

## Overview

### Useful For

Providing an isolate suitable for antimicrobial susceptibility testing to direct antimicrobial therapy of extraluminal infections and in cases of treatment failure

### Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
ANAID	Anaerobe Ident	No, (Bill Only)	No
RMALA	Id MALDI-TOF Mass Spec Anaerobe	No, (Bill Only)	No
ISAN	Anaerobe Ident by Sequencing	No, (Bill Only)	No
SANA	Anaerobe Suscep per agent	No, (Bill Only)	No
BATTA	Anaerobe Suscep Battery	No, (Bill Only)	No

### Testing Algorithm

When this test is ordered, the reflex tests may be performed at an additional charge. Isolates of *Clostridioides (Clostridium) difficile* (1,2) will automatically have susceptibility testing performed and billed as appropriate.

Antimicrobial agents appropriate to the organism and specimen source will be tested according to Mayo Clinic's practice and the laboratory's standard operating procedures.

See [Anaerobic Bacteria Antimicrobials](#), which provides a listing of the antimicrobials routinely tested in our laboratory as well as antimicrobials that may be tested upon request. If the antimicrobial of interest is not listed in this table, contact Mayo Clinic Laboratories at 800-533-1710 and ask to speak to the Bacteriology Anaerobe Laboratory.

The anaerobe susceptibilities battery is routinely performed at an additional charge. If fewer than 3 antibiotics are reported, then the anaerobe susceptibilities battery is canceled and anaerobe susceptibilities per agent will be charged per antibiotic tested. Based on susceptibility criteria, anaerobe susceptibilities per agent may be performed at an additional charge.

### Special Instructions

- [Anaerobic Bacteria Antimicrobials](#)

### Highlights

Culture provides definitive evidence of the presence of the bacterium *Clostridioides (Clostridium) difficile* in feces, providing an isolate for antimicrobial susceptibility testing.

Susceptibility testing of *C difficile* isolates may be warranted in cases of treatment failure or when used to guide therapy of extraluminal infections.

**Method Name**

Conventional Culture Technique with Minimal Inhibitory Concentration (MIC) by Agar Dilution

**NY State Available**

Yes

**Specimen****Specimen Type**

Varies

**Ordering Guidance**Culture is **not the preferred diagnostic test** for *Clostridioides difficile*. For routine diagnostic testing, order CDPCR / *Clostridioides difficile* Toxin, PCR, Feces**Necessary Information****Specimen source is required.****Specimen Required****Submit only 1 of the following specimens:****Patient Preparation:** Patient should **not** use antacids, barium, bismuth, antidiarrheal medication, zinc oxide paste, Vagisil cream or oily laxatives prior to specimen collection.**Preferred:****Specimen Type:** Preserved feces**Supplies:**

-Culture and Sensitivity Stool Transport Vial (T058)

-Stool Collection Kit, Random (T635)

**Container/Tube:** Commercially available transport system specific for recovery of enteric pathogens from fecal specimens (15 mL of non-nutritive transport medium containing phenol red as a pH indicator, either Cary-Blair or Para-Pak C and S [T058])**Specimen Volume:** Representative portion of feces; 5 mL**Collection Instructions:**

1. Collect fresh feces and submit 1 gram or 5 mL in container with transport medium.
2. Within 2 hours of collection, place feces in preservative.

**Specimen Stability Information:** Ambient (preferred) 96 hours/Refrigerated 96 hours/Frozen 7 days**Additional Information:** Only diarrheal (ie., unformed) feces should be tested. Testing formed feces for *Clostridioides difficile* is not clinically indicated.**Acceptable:****Specimen Type:** Unpreserved feces

**Supplies:**

- Stool container, Small (Random), 4 oz (T288)
- Stool Collection Kit, Random (T635)

**Container/Tube:** Stool container

**Specimen Volume:** Representative portion of stool

**Collection Instructions:** Collect fresh stool and submit representative sample in stool container.

**Specimen Stability Information:** Ambient (preferred) 72 hours/Frozen 7 days

**Additional Information:** Only diarrheal (i.e., unformed) stool should be tested. Testing formed stool for *Clostridioides difficile* is not clinically indicated.

**Specimen Type:** Fresh tissue or biopsy

**Sources:** Colon

**Supplies:** Anaerobe Transport Tube (T588)

**Specimen Volume:** Entire collection, 1 to 2 cm(3)

**Collection Instructions:** Aseptically collect 1 to 2 cm(3) piece of tissue whenever possible. In general, a larger piece of tissue is preferred. Submit in an anaerobic transport tube.

**Specimen Stability Information:** Ambient 72 hours

**Specimen Minimum Volume**

Stool: 1 gram or 5 mL; Tissue: 5 mm(3)

**Reject Due To**

Fecal swab	Reject
Specimen in Ecofix	Reject

**Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

**Clinical & Interpretive**

**Clinical Information**

*Clostridioides difficile* (previously *Clostridium difficile*) can cause diarrhea and may cause pseudomembranous colitis. Overgrowth of toxin-producing *C difficile* in the colon leads to the production of toxins A and/or B by the organism, and subsequent diarrhea. *C difficile* infection should be suspected in patients with symptoms of diarrhea with risk factors such as current or recent use of antibiotics, history of *C difficile* infection, current or recent hospitalization or placement in a nursing home or long-term care facility, age older than 65 years, and gastric acid suppression. *C difficile* infection is the most common cause of diarrhea in hospitalized patients and may lead to serious complications, including sepsis, bowel perforation, and increased overall mortality (especially in older patients). The incidence of *C difficile* infection has risen in the community and in healthcare settings. While culture is not the preferred means to diagnose *C*

---

*difficile*-associated diarrhea, culture for *C difficile* provides an isolate suitable for antimicrobial susceptibility testing.

Susceptibility testing routinely includes metronidazole and vancomycin. Routine antimicrobial susceptibility testing of *C difficile* isolates associated with intestinal infection is not suggested.(4,5) Recent Infectious Diseases Society of America and Society for Healthcare Epidemiology of America guidelines provide treatment guidance for *C difficile* infection based on clinical course and history rather than measured minimal inhibitory concentrations of isolates.(6) Susceptibility testing of *C difficile* isolates may be warranted in cases of treatment failure, or when used to guide therapy of extraluminal infections.

Note that this test does not differentiate between toxin-producing and nontoxigenic strains of *C difficile*.

### Reference Values

No growth of *Clostridioides difficile*.

Susceptibility results are reported as minimal inhibitory concentration (MIC) in mcg/mL. Breakpoints (also known as clinical breakpoints) are used to categorize an organism as susceptible, susceptible-dose dependent, intermediate, resistant, or nonsusceptible according to breakpoint setting organizations, either the Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial Susceptibility Testing (EUCAST), as applicable.

In some instances, an interpretive category cannot be provided based on available data; therefore, the following comment will be included on the report: There are no established interpretive guidelines for agents reported without interpretations.

For information regarding CLSI and EUCAST susceptibility interpretations, see [Susceptibility Interpretative Category Definitions](#).

### Interpretation

A positive result indicates the presence of viable *Clostridioides difficile* in stool.

A positive culture may be found with asymptomatic *C difficile* colonization with a toxin-producing or non-toxin-producing strain, or with *C difficile*-associated diarrhea.

A negative result indicates the absence of *C difficile* growth in culture.

Isolation of *C difficile* does not differentiate between toxin-producing and non-toxin-producing strains.

Refer to the Reference Values section for interpretation of various antimicrobial categories.

### Cautions

The assay must be performed on fresh feces, fresh-frozen feces, or feces in transport medium. Only diarrheal (ie, unformed) feces should be tested.

Submission of more than one specimen for testing is not recommended.

Repeated testing during a single episode of diarrhea is not recommended.

---

Testing of asymptomatic patients (ie, without diarrhea) or for test of cure is not recommended.

Patients may asymptotically carry *C difficile*.

Testing of specimens collected by colostomy, ileostomy, or colonoscopy has not been validated.

When antimicrobial susceptibilities are performed, in vitro susceptibility does not guarantee clinical response.

Therefore, the decision to treat with a particular agent should not be based solely on the antimicrobial susceptibility testing result.

### Supportive Data

Fifty fecal specimens in Cary Blair transport media that were previously determined as positive for *Clostridioides difficile* by toxin PCR were subcultured directly onto CHROMagar *C difficile* plates. Plates were incubated under anaerobic conditions at 37 degrees C for 24 hours in accordance with the manufacturer's recommendation. *C difficile* identification was performed by matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) directly from bacterial colony growth on CHROMagar plates. Using this method, *C difficile* was identified from 47 of 50 fecal specimens, corresponding to a 94% recovery rate. Two specimens that did not yield *C difficile* on CHROMagar media also failed to produce growth on conventional *C difficile* selective media (taurochocolate, cycloserine, ceftiofloxacin, fructose agar; TCCFA). One specimen was recovered by the TCCFA media, but not by the CHROMagar *C difficile* media. Organisms other than *C difficile* were not recovered on CHROMagar, corresponding to 100% analytical specificity.

Metronidazole clinical breakpoints are interpreted according to Clinical and Laboratory Standards Institute (CLSI) guidelines. For *C difficile*, an epidemiological cutoff value (ECV) of less than or equal to 2 mcg/mL (wild-type) and greater than or equal to 4 mcg/mL (non-wild type) is applied for vancomycin, according to CLSI guidelines. If *C difficile* strains were to acquire a resistance gene or undergo gene mutation resulting in reduced susceptibility, vancomycin minimal inhibitory concentration (MIC) values of greater than or equal to 4 mcg/mL would be expected. When considering vancomycin therapy for *C difficile* infection, clinical breakpoints have not been established due to lack of sufficient data on clinical outcomes by MIC.<sup>(7,8)</sup> It is suggested that susceptibility testing of *C difficile* isolates and interpretation of results be discussed with appropriate clinical specialists (eg, infectious diseases and/or pharmacy).

### Clinical Reference

1. Lawson PA, Citron DM, Tyrrell KL, Finegold SM. Reclassification of *Clostridium difficile* as *Clostridioides difficile* (Hall and O'Toole 1935) Prevot 1938. *Anaerobe*. 2016;40:95-99. doi:10.1016/j.anaerobe.2016.06.008
2. Oren A, Garrity GM. List of new names and new combinations previously effectively, but not validly, published. *Int J Syst Evol Microbiol*. 2016;66(7):2463-2466. doi:10.1099/ijsem.0.001149
3. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 32nd edition. CLSI Supplement M100. CLSI; 2023
4. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for *clostridium difficile* Infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis*. 2018;66(7):987-994
5. Schuetz AN, Carpenter DE. Susceptibility test methods: anaerobic bacteria. In: Carroll KC, Pfaller MA, eds. *Manual of Clinical Microbiology*. 12th ed. ASM Press; 2019:1377-1397
6. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guidelines by the Infectious Diseases Society of America

---

(IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of *Clostridioides difficile* infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044

7. Snyderman DR, McDermott LA, Jacobus NV, et al. U.S.-Based National Sentinel Surveillance Study for the epidemiology of *Clostridium difficile*-associated diarrheal isolates and their susceptibility to fidaxomicin. Antimicrob Agents Chemother. 2015;59(10):6437-6443. doi:10.1128/AAC.00845-15

8. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against *Clostridium difficile* and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother. 2013;57(10):4872-4876. doi:10.1128/AAC.01136-13

6. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of *Clostridioides difficile* infection in adults. Clin Infect Dis. 2021;73(5):e1029-e1044

## Performance

### Method Description

Specimens are directly inoculated onto a chromogenic *Clostridioides difficile* plate, which is incubated anaerobically at 35 to 37 degrees C for 24 hours. Plates are observed for characteristic fluorescence using ultraviolet light at 365 nm. Fluorescent colonies are identified by matrix-assisted laser desorption/ionization time-of-flight MALDI-TOF mass spectrometry or 16S ribosomal RNA gene sequencing. (Instruction manual: CHROMagar *C. difficile*, NT-EXT-077, Version 9, Available at [www.CHROMagar.com](http://www.CHROMagar.com))

The agar dilution method is used for routine susceptibility testing. The antimicrobial is added to agar in various concentrations depending upon levels attainable in serum. A standardized suspension of the organism is applied to the agar plates, which are incubated anaerobically for 42 to 48 hours at 35 to 37 degrees C. The end point is that in which a marked reduction occurs in the appearance of growth on the test plate as compared to that of growth on the control plate. Examples of marked change include a change from confluent growth to a haze, less than 10 tiny colonies, or 1 to 3 normal-sized colonies. (Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 9th ed. CLSI standard M11. CLSI; 2018)

### PDF Report

No

### Day(s) Performed

Monday through Sunday

### Report Available

2 to 9 days

### Specimen Retention Time

7 days

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Main Campus

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

### CPT Code Information

87081-C. difficile Culture

87076-Anaerobe Ident (if appropriate)

87076-Id MALDI-TOF Mass Spec Anaerobe (if appropriate)

87153-Anaerobe Ident by Sequencing (if appropriate)

87181-Anaerobe Susceptibility per agent (if appropriate)

87181 x 3-Antimicrobial Susceptibility, Anaerobic Bacteria, MIC (if appropriate)

### LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
CDIFS	C. difficile Culture + Susc	105047-5

Result ID	Test Result Name	Result LOINC® Value
CDIFS	C. difficile Culture + Susc	105047-5